Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C17H13F2NO3 |
| Molecular Weight | 317.2868 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
FC1(F)OC2=CC=C(C=C2O1)C(=O)NC3CC4=CC=CC=C4C3
InChI
InChIKey=OKCJNSDIVCXYAL-UHFFFAOYSA-N
InChI=1S/C17H13F2NO3/c18-17(19)22-14-6-5-12(9-15(14)23-17)16(21)20-13-7-10-3-1-2-4-11(10)8-13/h1-6,9,13H,7-8H2,(H,20,21)
| Molecular Formula | C17H13F2NO3 |
| Molecular Weight | 317.2868 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 20:38:16 GMT 2025
by
admin
on
Mon Mar 31 20:38:16 GMT 2025
|
| Record UNII |
GWD67BMF7L
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Code | English | ||
|
Preferred Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
3510704
Created by
admin on Mon Mar 31 20:38:16 GMT 2025 , Edited by admin on Mon Mar 31 20:38:16 GMT 2025
|
PRIMARY | |||
|
GWD67BMF7L
Created by
admin on Mon Mar 31 20:38:16 GMT 2025 , Edited by admin on Mon Mar 31 20:38:16 GMT 2025
|
PRIMARY | |||
|
450348-85-3
Created by
admin on Mon Mar 31 20:38:16 GMT 2025 , Edited by admin on Mon Mar 31 20:38:16 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
Mice were subjected to aortic banding to induce cardiac remodeling and were then administered AVE 3085 (10 mg kg day(-1), orally) for 4 weeks. At the end of the treatment, the aortic banding-treated mice exhibited significant elevations in cardiac remodeling, characterized by an increase in left ventricular weight relative to body weight, an increase in the area of collagen deposition, an increase in the mean myocyte diameter, and increases in the gene expressions of the hypertrophic markers atrial natriuretic peptide (ANP) and .BETA.-MHC. These indexes were significantly decreased in the AVE 3085-treated mice. Furthermore, AVE 3085 treatment reduced the expression and activation of the Smad signaling pathway in the aortic banding-treated mice. Our data showed that AVE 3085 attenuated cardiac remodeling, and this effect was possibly mediated through the inhibition of Smad signaling.
|
||
|
ACTIVE MOIETY |
Spontaneously hypertensive rats (SHRs) were treated with AVE 3085 (10 mg?kg?day(-1) , orally) for 4 weeks. KEY RESULTS: AVE3085 greatly improved endothelium-dependent relaxations in the aortae of SHRs. This functional change was accompanied by up-regulated expression of eNOS protein and mRNA, enhanced eNOS phosphorylation and decreased formation of nitrotyrosine. Furthermore, AVE3085 treatment reduced the blood pressure in SHR without affecting that of hypertensive eNOS(-/-) mice.
|
